| Info Sheets |
| | | | | | | | | | | | | | | | | | | | | | | | |
| Out- side |
| | | | |
|
| | | | |
Result : Searchterm 'iron oxide' found in 6 terms [] and 34 definitions []
| previous 16 - 20 (of 40) nextResult Pages : [1 2] [3 4 5 6 7 8] | | | | Searchterm 'iron oxide' was also found in the following service: | | | | |
| | |
| |
|
Short name: Ami 227, generic name: Ferumoxtran, (USPIO)
Ferumoxtran is a substance of the class of ultrasmall superparamagnetic iron oxide used as a lymph node specific contrast agent for MRI.
See also Combidex®, Sinerem® and Ultrasmall Superparamagnetic Iron Oxide.
Partner(s): Cytogen Corporation, National Cancer Institute.
An approvable letter was received from the U.S. Food and Drug Administration for Combidex in June 2000. Advanced Magnetics, Inc. has submitted a complete response to the approvable letter received from the U.S. Food and Drug Administration, which was accepted by the FDA and assigned a user fee goal date of March 30, 2005.
In Europe, a Dossier (the European equivalent of a NDA) was submitted by Advanced Magnetics' European partner, Guerbet SA, to the European Medicines Evaluations Agency in December 1999.
( Sinerem® is the brand name for this USPIO in Europe manufactured by Guerbet, Combidex® by Advanced Magnetics for the U.S. market)
Advanced Magnetics, Inc. changed its name in July 2007 to AMAG Pharmaceuticals Inc. | | | | | Further Reading: | | Basics:
|
|
News & More:
| |
| |
| | | | | |
| |
|
Generic name: Liposomes, central moiety: different, contrast effect: paramagnetic, distribution: different
Liposomes are lipid containing nanoparticles, or fat molecules, surrounding a water core. Liposomes were the first type of nanoparticles created to be used as carriers for lipophilic MRI contrast agents with novel characteristics.
Liposomes loaded with gadolinium-containing chelates have potential as blood pool agents, caused by modifications of the surface (e.g., with polyethylene glycol) leading to longer blood retention times.
The incorporation of contrast agents into either the the bilayer membrane or the aqueous inner cavity is possible. These MRI contrast agents has been used to image the lymph nodes using liposomes containing Gd-DTPA as well as dextran coated iron oxide particles.
To image the liver or the hepatobiliary system, liposomes containing Gd-HPDO3A, or MnDPDP, have been tested.
Liposomes containing gadolinium were conjugated to antibodies and targeted to a specific organ system.
A method of targeting tumors with ultrasound that also uses MRI to watch the cell destroying, uses liposomes loaded with cytotoxic drugs and also with gadolinium to make them show up in MRI. As well as used as an imaging technique, ultrasound can also be used to destroy cancer cells. Once the drugs have been administered, focusing the ultrasound on the target area makes blood vessels permeable. The liposomes leak out of the blood vessel into the target area, watched by MRI, where the cytotoxic drug can then go to work.
See also Memosomes, Superparamagnetic Iron Oxide, Classifications, Characteristics, etc. and Mangafodipir Trisodium. | | | | • View the DATABASE results for 'Liposomes' (6).
| | | • View the NEWS results for 'Liposomes' (1).
| | | | Further Reading: | Basics:
|
|
News & More:
| |
| |
| | | | | |
| |
|
| | | | • View the DATABASE results for 'Molecular Imaging' (10).
| | | • View the NEWS results for 'Molecular Imaging' (28).
| | | | Further Reading: | Basics:
|
|
News & More:
| |
| |
| | | Searchterm 'iron oxide' was also found in the following service: | | | | |
| | |
| |
|
Short name: NC100150, PEG-feron, generic name: Feruglose, preliminary trade name: Clariscanâ„¢
NC100150 injection is the code name for an USPIO ( ultrasmall superparamagnetic iron oxide) MRI contrast agent under development. Microvessel permeability depends on functional and morphologic characteristics of cancer vessels
and on physicochemical properties of the injected contrast medium molecule.
USPIO particles have a favorable pharmacological and tolerance profile and are being tested clinically of the potential for the quantitative
characterization of tumor microvasculature and specifically for measures of the microvessel permeability.
Iron-based products take advantage of their large molecular size, which prevents diffusion into body tissues. These agents are disposed of by the liver and spleen as particulate matter.
NC100150 Injection ( Nycomed Amersham, Amersham Health ) consists of USPIO particles that are composed of single crystals (4- to 7-nm diameter) and stabilized with a carbohydrate polyethylene glycol (PEG) coat. The iron oxide particles
have to be suspended in an isotonic glucose solution. The final diameter of an USPIO particle is approximately 20 nm. Blood pool half-life is more than two hours in humans; the particles are taken up by the mononuclear
phagocyte system and distributed mainly to the liver and spleen.
NC100150 would compete with the contrast agents Ferumoxytol from AMAG Pharmaceuticals, Inc. and Vasovistâ„¢ from EPIX Pharmaceuticals, Inc., but at this time the development of NC100150 Injection/ Clariscan™ is discontinued. | | | | • View the DATABASE results for 'NC100150 Injection' (5).
| | | • View the NEWS results for 'NC100150 Injection' (2).
| | | | |
| | | | | |
| |
|
| | | | • View the DATABASE results for 'Supravist™' (3).
| | | | |
| | | | |
| | | |
|
| |
| Look Ups |
| |